Results 131 to 140 of about 728 (161)

Effect of Aficamten in Women Compared with Men with Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM.

Circulation: Heart Failure
Background: Women with obstructive hypertrophic cardiomyopathy (oHCM) often present with a greater burden of disease and worse prognosis. Whether there are sex-related differences in response to aficamten is unknown. Methods: We performed a pre-specified
Xiaowen Wang, M. Pabón, Tracy T. Makuvire, Reziwanguli Maimaiti, T. Abraham, R. Barriales-Villa, B. Claggett, C. Coats, M. Maron, A. Masri, B. Meder, M. Nassif, I. Olivotto, A. Owens, S. Saberi, D. Jacoby, S. Heitner, S. Kupfer, F. Malik, A. Wohltman, S. Solomon, S. M. Hegde   +21 more
semanticscholar   +1 more source

Aficamten in patients with obstructive hypertrophic cardiomyopathy: an integrated safety analysis

European Heart Journal
Abstract Background Aficamten is a next-in-class, oral, selective cardiac myosin inhibitor targeting the hypercontractility underlying hypertrophic cardiomyopathy (HCM). It relieves left ventricular outflow tract obstruction, improves exercise capacity, symptoms, quality of life, and cardiac ...
A Masri, R Barriales-Villa, P Elliott, M E Nassif, A T Owens, A Oreziak, A Tower-Rader, M Chiu, S B Heitner, S Kupfer, F I Malik, C Melloni, L Meng, A Wohltman, S Saberi   +14 more
openaire   +1 more source

Abstract 4336093: Effect of Aficamten in Women Compared with Men with Obstructive Hypertrophic Cardiomyopathy

Circulation
Background: Women with obstructive hypertrophic cardiomyopathy (oHCM) may present with a greater burden of disease and carry a worse prognosis. Whether there are sex-related differences in response to aficamten is unknown.
Xiaowen Wang, M. Pabon, T. Abraham, R. Barriales-Villa, B. Claggett, C. Coats, M. Maron, Ahmad Masri, B. Meder, M. Nassif, I. Olivotto, D. Jacoby, S. Heitner, A. Wohltman, Scott D. Solomon, Sheila M. Hegde   +15 more
semanticscholar   +1 more source

Efficacy and safety of long-term treatment with aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy: results from FOREST-HCM

European Heart Journal
Aficamten is a next-in-class, oral selective cardiac myosin inhibitor developed to treat symptomatic hypertrophic cardiomyopathy (HCM). To assess safety and efficacy of long-term treatment with aficamten in patients with symptomatic ...
A. Tower-Rader, A. Masri, M. Nassif, T. Abraham, R. Barriales-Villa, L. Choudhury, R. Cooper, P. Elliott, M. Maron, I. Olivotto, A. Oręziak, A. Owens, S. Solomon, C. Melloni, S. Saberi   +14 more
semanticscholar   +1 more source

Abstract 4364366: Myosin modulator Aficamten inhibits force in cardiac muscle by altering myosin’s biochemical activity without changing thick filament structure

Circulation
Introduction: Inhibiting contractility by targeting cardiac myosin is an effective treatment for patients with hypertrophic cardiomyopathy (HCM). Aficamten (Afi), a second in class myosin inhibitor, improves hemodynamics and symptoms in HCM patients ...
Saffie Mohran, Kristina B. Kooiker, Anthony M. Asencio, Ateeqa Naim, Matvey Pilagov, Weikang Ma, Thomas Irving, Neil M Kad, M. Regnier, F. Moussavi-Harami   +9 more
semanticscholar   +1 more source

Abstract 4365842: Chronic Aficamten Treatment Results in Sustained Favorable Cardiac Remodeling in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights From the FOREST-HCM Trial

Circulation
Background: Aficamten treatment over 24 weeks in SEQUOIA-HCM (NCT05186818) improved left ventricular (LV) outflow tract gradients (LVOT-G), showed evidence of favorable cardiac remodeling, and improved measures of LV diastolic function in patients ...
Sheila M. Hegde, M. Pabon, Ahmad Masri, M. Nassif, T. Abraham, R. Barriales-Villa, R. Cooper, P. Elliott, M. Maron, A. Oręziak, Anjali Owens, Albree Tower Rader, S. Heitner, D. Jacoby, S. Kupfer, Xueli Liu, F. Malik, C. Melloni, Tyrell Simkins, Jenny Wei, Scott D. Solomon, S. Saberi   +21 more
semanticscholar   +1 more source

Auch Aficamten (Myosininhibitor) hocheffektiv und sicher bei HOCM

Aktuelle Kardiologie, 2023
openaire   +1 more source

Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy

Journal of Medicinal Chemistry, 2021
Chihyuan Chuang, Scott E Collibee, Darren T Hwee   +2 more
exaly  

AFICAMTEN IN PATIENTS WITH SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (REDWOOD-HCM COHORT 4)

Journal of the American College of Cardiology, 2023
Ahmad Masri, Mark V. Sherrid, Lubna Choudhury, Florian Rader, Christopher M. Kramer, Sara Saberi, Timothy C. Wong, Aslan Teyfik Turer, Sherif F. Nagueh, Anjali Tiku Owens, Caroline Coats, Iacopo Olivotto, Hugh Watkins, Michael A. Fifer, Scott D. Solomon, Theodore P. Abraham, Steve Heitner, Dan Jacoby, Stuart Kupfer, Fady I. Malik, Lisa Meng, Regina L. Sohn, Amy Wohltman, Martin S. Maron   +23 more
openaire   +1 more source

Aficamten reduces cardiac contractility by modifying the actomyosin interaction

Nature Cardiovascular Research
Farid Moussavi-Harami, Michael Regnier
openaire   +1 more source